COLL

Collegium Pharmaceutical (COLL) closed at $23.18 with a mean analyst price target of $49, suggesting 111.4% upside potential. The stock has a Zacks Rank #1 (Strong Buy) rating and shows positive earnings estimate revisions, with the consensus estimate for the current year increasing 3.8% over the last 30 days. However, the article cautions that price targets alone should not be the sole basis for investment decisions.

Zacks has added three stocks to its Strong Sell list today: Ardelyx (ARDX), a biopharmaceutical company with a 53.9% downward earnings revision; Southwest Airlines (LUV), a passenger airline with a 4.1% downward earnings revision; and Collegium Pharmaceutical (COLL), a specialty pharmaceutical company with a nearly 3% downward earnings revision over the last 60 days.